Abstract:Objective: To study the preventive effect of mecobalamin on peripheral neuropathy (CIPN) induced by oxaliplatin + capecitabine (XELOX) regimen in patients with colorectal cancer. Methods: A total of 76 patients with colorectal cancer who were admitted to the Fourth Affiliated Hospital of Guangzhou Medical University from January 2020 to January 2022 were selected and divided into observation group and control group according to the random number table method,with 38 cases in each group.The control group was treated with XELOX regimen,and the observation group was treated with Mecobalamin Combined with XELOX regimen.After six chemotherapy cycles,the incidence of CIPN,nerve conduction velocity,level of inflammatory factors and incidence of adverse reactions were evaluated and compared among the groups. Results: The incidence of CIPN of grade II,III and IV in the observation group was lower than that in the control group (P<0.05).After treatment,the SNCV,MNCV of the median nerve and sural nerve in the observation group were higher than those in the control group (P<0.05).The levels of Nod-like receptor protein 3 (NLRP3),hypoxia-inducible factor-1α (HIF-1α) and B cell activating factor receptor (BAFF-R) in the observation group were lower than those in the control group (P<0.05).The scores of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC QLQ-C30) in the observation group were higher than those in the control group (P<0.05).During the treatment,the incidence of adverse reactions was 15.79% (6/38) in the observation group and 10.53% (4/38) in the control group,with no significant difference (P>0.05). Conclusion: Mecobalamin has a significant preventive effect on CIPN of XELOX regimen in patients with colorectal cancer.It can reduce the incidence of CIPN,and it can improve peripheral nerve conduction velocity,and it can inhibit the level of related inflammatory factors,and it can improve the quality of life of patients,and it has high clinical value.
[1] Marc V D W,Francies H E,Francis J M,et al.Prospective derivation of a living organoid biobank of colorectal cancer patients[J].Cell,2020,61(4):933-945. [2] 阎欣,刘晓阳,杨星昱,等.腓肠神经传导速度检测在评估奥沙利铂诱导性周围神经病中的价值[J].大连医科大学学报,2020,42(3):1915-1919. [3] 梁翠绿,张吟,陈文发.药物防治化疗所致周围神经病变的临床研究进展[J].中国现代应用药学,2021,29(11):2812-2817. [4] 杨荣源,陈进鸿,李洪瀚.绿茶多酚联合甲钴胺对周围神经损伤修复作用的动物实验研究[J].中华手外科杂志,2020,36(1):61-65. [5] 中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范(2020版)[J].中华消化外科杂志,2020,29(6):563-588. [6] Chen L,Bai P,Kong X,et al.Prognostic nutritional Index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator[J].Frontiers in Cell and Developmental Biology,2021,9(12):656-661. [7] Ameri H,Yousefi M,Yaseri M,et al.Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in colorectal cancer patients[J].Gastrointest Cancer,2020,51(1):196-203. [8] Ontario H Q.KRAS testing for anti-EGFR therapy in advanced colorectal cancer:an evidence-based and economic analysis.[J].Ontario health technology assessment series,2020,20(25):41-49. [9] Chandak D,Sharma P.Development and validation for simultaneous estimation of gabapentin,mecobalamin and alpha lipoic acid in tablet formulation[J].Research Journal of Science and Technology,2020,12(1):74-79. [10] Mai W,Wei A,Lin X,et al.Efficacy and safety of traditional Chinese medicine injection with mecobalamin in treating diabetic peripheral neuropathy:a protocol for systematic review and meta-analysis[J].Medicine,2021,100(1):702-709. [11] 张颖,刘小溪,张兰.血塞通定向透药导入疗法联合甲钴胺治疗糖尿病周围神经病变疗效观察[J].现代中西医结合杂志,2021,30(11):611-616. [12] Li L,Shan S,Kang K,et al.The cross-talk of NLRP3 inflammasome activation and necroptotic hepatocyte death in acetaminophen-induced mice acute liver injury:[J].Human & Experimental Toxicology,2021,40(4):673-684. [13] Roy S,Rizvi Z A,Clarke A J,et al.EGFR-HIF1α signaling positively regulates the differentiation of IL-9 producing T helper cells[J].Nature Communications,2021,12(1):181-187. [14] Wang Y,Jia X,Zhou L,et al.Increased let-7b-5p is associated with enhanced BAFF-R expression and B cell survival in immune thrombocytopenia[J].International Immunopharmacology,2021,93(2):107-113.